0001493152-25-003376.txt : 20250123 0001493152-25-003376.hdr.sgml : 20250123 20250123154558 ACCESSION NUMBER: 0001493152-25-003376 CONFORMED SUBMISSION TYPE: SCHEDULE 13G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20250123 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Phio Pharmaceuticals Corp. CENTRAL INDEX KEY: 0001533040 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SCHEDULE 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-86901 FILM NUMBER: 25549913 BUSINESS ADDRESS: STREET 1: 11 APEX DRIVE, SUITE 300A STREET 2: PMB 2006 CITY: MARLBOROUGH STATE: MA ZIP: 01752 BUSINESS PHONE: (508) 767-3861 MAIL ADDRESS: STREET 1: 11 APEX DRIVE, SUITE 300A STREET 2: PMB 2006 CITY: MARLBOROUGH STATE: MA ZIP: 01752 FORMER COMPANY: FORMER CONFORMED NAME: RXi Pharmaceuticals Corp DATE OF NAME CHANGE: 20111019 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Orca Capital AG CENTRAL INDEX KEY: 0002052389 ORGANIZATION NAME: IRS NUMBER: 000000000 STATE OF INCORPORATION: 2M FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SCHEDULE 13G BUSINESS ADDRESS: STREET 1: SPERLRING 2 CITY: PFAFFENHOFEN STATE: 2M ZIP: 85276 BUSINESS PHONE: 498441 78644 14 MAIL ADDRESS: STREET 1: SPERLRING 2 CITY: PFAFFENHOFEN STATE: 2M ZIP: 85276 SCHEDULE 13G 1 primary_doc.xml SCHEDULE 13G 0002052389 XXXXXXXX LIVE Common Stock, par value $0.0001 per share 12/19/2024 0001533040 Phio Pharmaceuticals Corp. 71880W501 11 Apex Drive, Suite 300A, PMB 2006 Marlborough MA 01752 Rule 13d-1(c) Orca Capital AG 2M 514965.00 0.00 514965.00 0.00 514965.00 N 9.9 CO Phio Pharmaceuticals Corp. 11 Apex Drive, Suite 300A, PMB 2006 Marlborough, Massachusetts 01752 Orca Capital AG Sperlring 2 85276 Hettenshausen Deutschland Germany Y 514,965 From December 19, 2024 to the date of this Schedule, the Reporting Person acquired the Issuer's Common Stock in the following amounts: 109,298 shares, 60,000 shares, 350 shares, 332,668 shares, 244,445 shares, and 152,500 shares. During the same period, the Reporting Person disposed of the Issuer's Common Stock in the following amounts: 29,316 shares, 9,825 shares, 130,157 shares, 350 shares, 332,668 shares, 151,597 shares, 200 shares, 92,848 shares, 8,800 shares, and 6,500 shares. The foregoing excludes shares of Common Stock issuable upon the exercise of certain warrants containing blocker provisions. The Reporting Person does not have the right to exercise warrants for 474,298 shares of Common Stock and 776,261 shares of Common Stock to the extent that such exercises would result in beneficial ownership of the Issuer's Common Stock by the Reporting Person of more than 4.9% or 9.9%, respectively. 9.9 514,965 0 514,965 0 Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Orca Capital AG /s/ Thomas Konig 01/23/2025